HK1248546A1 - Wt1抗原肽和免疫調節劑的組合 - Google Patents
Wt1抗原肽和免疫調節劑的組合Info
- Publication number
- HK1248546A1 HK1248546A1 HK18108240.1A HK18108240A HK1248546A1 HK 1248546 A1 HK1248546 A1 HK 1248546A1 HK 18108240 A HK18108240 A HK 18108240A HK 1248546 A1 HK1248546 A1 HK 1248546A1
- Authority
- HK
- Hong Kong
- Prior art keywords
- immunomodulator
- combination
- antigen peptide
- antigen
- peptide
- Prior art date
Links
- 239000000427 antigen Substances 0.000 title 1
- 102000036639 antigens Human genes 0.000 title 1
- 108091007433 antigens Proteins 0.000 title 1
- 239000002955 immunomodulating agent Substances 0.000 title 1
- 229940121354 immunomodulator Drugs 0.000 title 1
- 230000002584 immunomodulator Effects 0.000 title 1
- 108090000765 processed proteins & peptides Proteins 0.000 title 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/82—Translation products from oncogenes
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2015103145 | 2015-05-20 | ||
PCT/JP2016/064923 WO2016186177A1 (ja) | 2015-05-20 | 2016-05-19 | Wt1抗原ペプチドおよび免疫調節剤の併用 |
Publications (1)
Publication Number | Publication Date |
---|---|
HK1248546A1 true HK1248546A1 (zh) | 2018-10-19 |
Family
ID=57320344
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18107308.2A HK1250213A1 (zh) | 2015-05-20 | 2018-06-05 | Wt1抗原肽和免疫調節劑的組合 |
HK18108240.1A HK1248546A1 (zh) | 2015-05-20 | 2018-06-27 | Wt1抗原肽和免疫調節劑的組合 |
Family Applications Before (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HK18107308.2A HK1250213A1 (zh) | 2015-05-20 | 2018-06-05 | Wt1抗原肽和免疫調節劑的組合 |
Country Status (7)
Country | Link |
---|---|
US (1) | US20180140691A1 (zh) |
EP (1) | EP3299028A4 (zh) |
JP (4) | JP6515182B2 (zh) |
CN (1) | CN107921106B (zh) |
CA (1) | CA2986367A1 (zh) |
HK (2) | HK1250213A1 (zh) |
WO (1) | WO2016186177A1 (zh) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2907782C (en) | 2013-03-29 | 2021-01-05 | Sumitomo Dainippon Pharma Co., Ltd. | Wt1 antigen peptide conjugate vaccine |
AU2016356708B2 (en) | 2015-11-20 | 2022-02-03 | Memorial Sloan Kettering Cancer Center | Methods and compositions for treating cancer |
US11364304B2 (en) | 2016-08-25 | 2022-06-21 | Northwestern University | Crosslinked micellar spherical nucleic acids |
EP3549957A4 (en) * | 2016-11-30 | 2020-08-05 | Sumitomo Dainippon Pharma Co., Ltd. | WT1-HELPER PEPTIDE AND COMBINATION OF THE SAYING PEPTIDE AND A CANCER ANTIGEN PEPTIDE CONJUGATE |
MY192920A (en) * | 2017-03-15 | 2022-09-15 | Cancer Res Malaysia | Immunogenic peptide composition |
US11696954B2 (en) | 2017-04-28 | 2023-07-11 | Exicure Operating Company | Synthesis of spherical nucleic acids using lipophilic moieties |
IL310079A (en) * | 2017-08-28 | 2024-03-01 | Bristol Myers Squibb Co | TIM-3 antagonists for the treatment and diagnosis of cancer |
LT3691620T (lt) * | 2017-10-05 | 2022-09-26 | Fulcrum Therapeutics, Inc. | P38 kinazės inhibitoriai, sumažinantys dux4 ir pasrovinių genų raišką, skirti fshd gydymui |
KR102184377B1 (ko) * | 2018-02-19 | 2020-11-30 | 고려대학교 산학협력단 | 열충격단백질의 에피토프를 포함하는 백신 및 이의 용도 |
KR20210068060A (ko) | 2018-09-28 | 2021-06-08 | 다이니뽄 스미토모 세이야쿠 가부시키가이샤 | 주사용 조성물 |
AU2019352354A1 (en) * | 2018-10-05 | 2021-05-13 | International Institute Of Cancer Immunology, Inc. | Prophylactic or therapeutic drug for benign tumor |
US20220168408A1 (en) * | 2019-04-10 | 2022-06-02 | Slsg Limited Llc | Multi-valent immunotherapy composition and methods of use for treating wt1-positive cancers |
WO2021021924A1 (en) * | 2019-07-29 | 2021-02-04 | Huang Cai Gu | Formulation of antibody based drugs for treating lung cancer by inhalation |
CN114945383A (zh) | 2019-12-10 | 2022-08-26 | 住友制药株式会社 | 肽乳液制剂的调制方法 |
US20230255978A1 (en) * | 2020-05-12 | 2023-08-17 | Board Of Regents, The University Of Texas System | Methods for treating glioblastoma |
CN111647066B (zh) * | 2020-07-01 | 2020-12-18 | 维肽瀛(上海)生物技术有限公司 | Wt1多肽肿瘤抑制剂 |
KR20230163364A (ko) * | 2021-03-31 | 2023-11-30 | 셀레론 테라퓨틱스 리미티드 | 백신 보조제 |
Family Cites Families (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2511538C (en) * | 2002-12-30 | 2013-11-26 | 3M Innovative Properties Company | Immunostimulatory combinations |
DE602004023476D1 (de) * | 2003-01-15 | 2009-11-19 | Chugai Pharmaceutical Co Ltd | Dimerisiertes peptid |
CA2520172C (en) * | 2003-03-27 | 2012-10-02 | Lankenau Institute For Medical Research | Novel methods for the treatment of cancer with an indoleamine 2, 3-dioxygenase inhibitor |
US20040197312A1 (en) * | 2003-04-02 | 2004-10-07 | Marina Moskalenko | Cytokine-expressing cellular vaccine combinations |
AU2004255470B2 (en) * | 2003-07-10 | 2010-08-19 | Cytos Biotechnology Ag | Packaged virus-like particles |
EP1670513B1 (en) * | 2003-10-06 | 2013-01-23 | Cedars-Sinai Medical Center | Cox-2 inhibitors and dendritic cells for use in the treatment of cancer. |
MX2008013993A (es) * | 2006-05-03 | 2009-05-11 | Univ Colorado | Combinación adyuvante sinergistica de anticuerpo agonista de cd40/interferona tipo 1, conjugados que la contienen y uso de los mismos como un terapeutico para aumentar la inmunidad celular. |
JP5427027B2 (ja) * | 2006-05-03 | 2014-02-26 | ザ・リージェンツ・オブ・ザ・ユニバーシティ・オブ・コロラド,ア・ボディー・コーポレイト | Cd40アゴニスト抗体/i型インターフェロン相乗性アジュバントの結合体、それを含む複合体、および細胞性免疫を強化する治療としてのその使用 |
GB0620894D0 (en) * | 2006-10-20 | 2006-11-29 | Univ Southampton | Human immune therapies using a CD27 agonist alone or in combination with other immune modulators |
DK2370593T3 (en) * | 2008-11-28 | 2016-07-04 | Univ Emory | A method for determining the effect of PD-1 Antagonists |
KR101208587B1 (ko) * | 2009-06-24 | 2012-12-06 | 여오영 | 하이드록시클로로퀸을 포함하는 항암 치료를 위한 국소 투여용 주사제 조성물 |
BR112012026227A2 (pt) * | 2010-04-13 | 2020-08-04 | Celldex Therapeutics, Inc. | anticorpo monoclonal humano ou humanizado, molécula biespecífica, vetor de expressão, célula transformada, composição, e, usos de um anticorpo |
CN103157108B (zh) * | 2011-12-13 | 2016-01-20 | 宁云山 | 免疫调节剂组合物及其药物组合物和应用 |
CA2858876A1 (en) * | 2011-12-15 | 2013-06-20 | The University Of Chicago | Methods and compositions for cancer therapy using mutant light molecules with increased affinity to receptors |
AR090263A1 (es) * | 2012-03-08 | 2014-10-29 | Hoffmann La Roche | Terapia combinada de anticuerpos contra el csf-1r humano y las utilizaciones de la misma |
CN103830211A (zh) * | 2012-11-27 | 2014-06-04 | 上海曼克尔瑞生物医药技术有限公司 | 一种β-catenin蛋白抑制剂-姜黄素在肝癌治疗方面的应用 |
RU2687026C2 (ru) * | 2013-02-05 | 2019-05-06 | Нитто Денко Корпорейшн | Вакцинная композиция против злокачественной опухоли на основе пептида wt1 для мукозального введения |
KR102363191B1 (ko) * | 2013-02-26 | 2022-02-17 | 메모리얼 슬로안 케터링 캔서 센터 | 면역치료용 조성물 및 방법 |
CA2907782C (en) * | 2013-03-29 | 2021-01-05 | Sumitomo Dainippon Pharma Co., Ltd. | Wt1 antigen peptide conjugate vaccine |
JP2016527303A (ja) * | 2013-08-05 | 2016-09-08 | ケンブリッジ エンタープライズ リミテッド | がん免疫療法におけるcxcr4シグナル伝達の阻害 |
-
2016
- 2016-05-19 WO PCT/JP2016/064923 patent/WO2016186177A1/ja active Application Filing
- 2016-05-19 JP JP2017519401A patent/JP6515182B2/ja active Active
- 2016-05-19 CN CN201680042322.XA patent/CN107921106B/zh active Active
- 2016-05-19 CA CA2986367A patent/CA2986367A1/en active Pending
- 2016-05-19 US US15/575,162 patent/US20180140691A1/en active Pending
- 2016-05-19 EP EP16796570.6A patent/EP3299028A4/en active Pending
-
2018
- 2018-06-05 HK HK18107308.2A patent/HK1250213A1/zh unknown
- 2018-06-27 HK HK18108240.1A patent/HK1248546A1/zh unknown
-
2019
- 2019-04-15 JP JP2019076826A patent/JP6713160B2/ja active Active
-
2020
- 2020-01-29 JP JP2020012396A patent/JP6956967B2/ja active Active
-
2021
- 2021-09-22 JP JP2021154508A patent/JP7253210B2/ja active Active
Also Published As
Publication number | Publication date |
---|---|
JP6515182B2 (ja) | 2019-05-15 |
EP3299028A1 (en) | 2018-03-28 |
US20180140691A1 (en) | 2018-05-24 |
CA2986367A1 (en) | 2016-11-24 |
CN107921106A (zh) | 2018-04-17 |
JP2022000454A (ja) | 2022-01-04 |
HK1250213A1 (zh) | 2018-12-07 |
JP2019135251A (ja) | 2019-08-15 |
WO2016186177A1 (ja) | 2016-11-24 |
JP6956967B2 (ja) | 2021-11-02 |
JP7253210B2 (ja) | 2023-04-06 |
EP3299028A4 (en) | 2019-02-27 |
JP2020075934A (ja) | 2020-05-21 |
JPWO2016186177A1 (ja) | 2018-04-12 |
JP6713160B2 (ja) | 2020-06-24 |
CN107921106B (zh) | 2023-09-08 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1248546A1 (zh) | Wt1抗原肽和免疫調節劑的組合 | |
IL249032A0 (en) | ras inhibitory peptides and their uses | |
IL284236A (en) | Modifications and uses of conotoxin peptides | |
HK1251979A1 (zh) | 肽組合物和使用方法 | |
GB201621707D0 (en) | Synthesis and use of amino lipids | |
IL259096A (en) | Peptides and methods of treating endometriosis using the same | |
IL287985A (en) | A peptide derived from koc1 and a component containing it | |
IL284792A (en) | Peptide derivative - DEPDC1 and a component containing it | |
IL250215A0 (en) | A peptide derived from cdca1 and a component containing it | |
IL251289A0 (en) | New peptide derivatives and their use | |
PT3430390T (pt) | Origem molecular da alergia | |
IL250235A0 (en) | A peptide derived from urlc10 and a component containing it | |
IL247448A0 (en) | Peptides and methods of use | |
GB201421888D0 (en) | Peptides derived from mysoin 19 and methods of use thereof | |
SG11201610918RA (en) | Peptides and uses thereof | |
GB201401673D0 (en) | Esculentin-2CHa peptide and analogues thereof | |
AU2015901160A0 (en) | Immunomodulatory peptides and methods of use | |
GB201504211D0 (en) | Use of peptides |